Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00357188
Status:
COMPLETED
Last Update Posted:
2011-04-08
First Post:
2006-07-26
Brief Title:
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz ATVRTV EFV in Healthy Subjects
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Open-Label Multiple Dose Study to Determine the Relative Bioavailability of Atazanavir ATV 400 mg Administered With Ritonavir RTV and Efavirenz EFV Compared to Atazanavir 300 mg Administered With Ritonavir Alone in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None